Cutanea

Cutanea Life Sciences, Inc. is a specialty pharmaceutical company in the development stage, focused on licensing and developing treatments for dermatological conditions. The company's lead product candidate is omiganan (CLS001), which is being prepared for a Phase III clinical study to treat rosacea and has plans for a Phase II clinical study to treat atopic dermatitis.